September is prostate cancer awareness month.
A prostate cancer diagnosis often comes with the tough decision about whether to treat it with surgery or radiation, or safely monitor it using ‘active surveillance’.
Now, there’s a test that may help make those decisions easier.
A ‘Genomic test’ can look at the genes to determine the aggressiveness of the cancer.
Many men opt to treat their prostate cancer because they’re afraid of dying from the disease, even though their tumor may be slow growing and never cause any harm.
There are currently two genomic tests available that grade the aggressiveness of a cancer once it has been diagnosed through a biopsy.
According to the American Cancer Society more than 238-thousand new cases of prostate cancer will be diagnosed in the U.S. this year.